Abstract
There is increasing evidence that antimicrobial peptides (AMPs) are differentially regulated in cancers such as oral squamous cell carcinomas (OSCC). Data showing that AMPs influence the growth of tumor cells, exhibit direct cytotoxic activity towards cancer cells, function as a tumor suppressor gene or activate the adaptive immunity suggest that a dysregulation of AMPs may be associated with the development of cancer. There is no question that, with increasing resistance against conventional chemotherapy, novel anticancer agents are needed. It is interesting to speculate that natural AMP or synthetic derivatives can be used to develop novel strategies to fight cancer diseases and may represent a novel family of anticancer agents. However, future research is needed to employ the role of AMPs in cancer and to investigate their role as potential anticancer drugs.
Keywords: Antimicrobial peptide, defensin, cathelicidin, histatin, adrenomedullin, oral cancer, immunotherapy, anticancer effect
Current Pharmaceutical Design
Title: Antimicrobial Peptides in Oral Cancer
Volume: 13 Issue: 30
Author(s): Jens E. Meyer and Jurgen Harder
Affiliation:
Keywords: Antimicrobial peptide, defensin, cathelicidin, histatin, adrenomedullin, oral cancer, immunotherapy, anticancer effect
Abstract: There is increasing evidence that antimicrobial peptides (AMPs) are differentially regulated in cancers such as oral squamous cell carcinomas (OSCC). Data showing that AMPs influence the growth of tumor cells, exhibit direct cytotoxic activity towards cancer cells, function as a tumor suppressor gene or activate the adaptive immunity suggest that a dysregulation of AMPs may be associated with the development of cancer. There is no question that, with increasing resistance against conventional chemotherapy, novel anticancer agents are needed. It is interesting to speculate that natural AMP or synthetic derivatives can be used to develop novel strategies to fight cancer diseases and may represent a novel family of anticancer agents. However, future research is needed to employ the role of AMPs in cancer and to investigate their role as potential anticancer drugs.
Export Options
About this article
Cite this article as:
Meyer E. Jens and Harder Jurgen, Antimicrobial Peptides in Oral Cancer, Current Pharmaceutical Design 2007; 13 (30) . https://dx.doi.org/10.2174/138161207782110372
DOI https://dx.doi.org/10.2174/138161207782110372 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents
Current Medicinal Chemistry Recent Patents on Cell Cycle Regulatory Proteins
Recent Patents on Biotechnology Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry Molecular Testing and Personalized Treatment of Lung Cancer
Current Molecular Pharmacology Lactoferrin: A Biologically Active Molecule for Bone Regeneration
Current Medicinal Chemistry Non-Small Cell Lung Cancer: From Cytotoxic Systemic Chemotherapy to Molecularly Targeted Therapy
Current Medicinal Chemistry - Anti-Cancer Agents The Metastatic Process: Methodological Advances and Pharmacological Challenges
Current Medicinal Chemistry Metal Allergens of Growing Significance: Epidemiology, Immunotoxicology, Strategies for Testing and Prevention
Inflammation & Allergy - Drug Targets (Discontinued) Evaluating the Susceptibility of Mitochondrial DNA Germline Mutations in Chinese Cancer Patients
Current Molecular Medicine Use of Etanercept in the Treatment of Psoriasis and Psoriatic Arthritis
Reviews on Recent Clinical Trials Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors
Current Pharmaceutical Design Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis
Current Pharmaceutical Design Incidentally Detected Increased FDG Uptake in Bowel and its Correlation with Hystopathological Data: Our Experience in a Case Series Study
Current Radiopharmaceuticals MRI Evaluation Using DWI and T2WI of Residual Lymph Nodes in patients Affected by Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy
Current Medical Imaging Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Targeting STAT1 in Both Cancer and Insulin Resistance Diseases
Current Protein & Peptide Science Antiangiogenesis Potential of Alpinumisoflavone as an Inhibitor of Matrix Metalloproteinase-9 (MMP-9) and Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2)
Current Enzyme Inhibition The Cytotoxicity and Synergistic Potential of Aspirin and Aspirin Analogues Towards Oesophageal and Colorectal Cancer
Current Clinical Pharmacology <i>Cosmos Caudatus</i>: A Possible Drug Candidate for Oral Squamous Cell Carcinoma
Current Bioactive Compounds